Abstract:Background and Aims: Recent studies have shown epsterin-Barr virus (EBV) infection is related to the development of gastric cancer. In particular, latent EBV infection usually established persistently and promoted tumor progression. The zinc finger E-box binding factor 1 (ZEB1) mediated transcriptional silencing of intermediate-early genes and induced EBV infection from lytic to latent stage. We aim to study the effect of ZEB1 on modulating latent-lytic switch in gastric cancer, and to explore the potential of ZEB1 as a novel molecular target for the intervention of EBV associated Gastric Cancer (EBVaGc). Method Gastric cancer cell-lines with latent (YCC10 cell-line) and lytic (AGS-EBV infected cell-line) EBV infection were used in this study. Loss or gain function of ZEB1 was obtained by ZEB1 siRNA knockdown or forced re-expression experiments, respectively. The modulation of the intermediateearly gene and apoptotic mediators were assessed by real time RT-PCR and Western blot. Cell growth was evaluated by cell viability assay and colony formation assay, and cell cycle by flow cytometry analysis. Results: siRNA-mediated knockdown of ZEB1 in latent EBV infected cell-line YCC10 triggered a 3-fold enhanced expression of BZLF1, an intermediateearly gene of EBV, but a 5-fold reduction in expression of EBV nuclear antigen 1 (EBNA1), a gene that plays essential roles in enabling the replication and persistence of EBV genomes in latently infected cells and activating EBV latent gene expression. By doing so, knockdown of ZEB1 in YCC10 significantly inhibited cell viability (100% to 84%, P<0.01), suppressed cell proliferation as evidenced by reduced S phase cells (P=0.005), caused cell cycle arrest in G2M phase (P=0.006) and induced cell apoptosis (4.6±0.15% to 7.1±1.36%, P<0.05), The induction of cell apoptosis is confirmed by the cleavage of caspase-3 and PARP. On the other hand, over-expression of ZEB1 in lytic EBV infected cell line AGS-EBV through transient transfection significantly increased cell viability (P<0.01), induced S phase cell number (32.9±1.17% to 40.3±23.89%, P<0.05) and promoted colony formation (P<0.01). Conclusion: ZEB1 is involved in the latent-lytic switch of EBV associated gastric cancer. Inhibition of ZEB1 may be a promising approach for the treatment of EBVaGc.

Effect of EBV LMP1 Targeted DNAzymes on Cell Proliferation and Apoptosis

Deoxyribozymes targeted to EBV-LMP1 mRNA induce apoptosis and enhance radiosensitivity in LMP1-positive cells

DNAzymes targeted to EBV-encoded latent membrane protein-1 induce apoptosis and enhance radiosensitivity in nasopharyngeal carcinoma.

A Therapeutic Approach to Nasopharyngeal Carcinomas by DNAzymes Targeting EBV LMP-1 Gene

Therapeutic evaluation of Epstein-Barr virus-encoded latent membrane protein-1 targeted DNAzyme for treating of nasopharyngeal carcinomas.

M1912 Role of Zinc Finger E-Box Binding Factor 1 Modulating Latent-Lytic Switch of Epstein-Barr Virus in Gastric Cancer

siRNA targeting LMP1-induced apoptosis in EBV-positive lymphoma cells is associated with inhibition of telomerase activity and expression.

EBV-LMP1-targeted DNAzyme Induces DNA Damage and Causes Cell Cycle Arrest in LMP1-positive Nasopharyngeal Carcinoma Cells.

Targeting Ebv-Lmp1 Dnazyme Enhances Radiosensitivity Of Nasopharyngeal Carcinoma Cells By Inhibiting Telomerase Activity

Epstein-Barr Virus Lmp1 Initiates Cell Proliferation and Apoptosis Inhibition Via Regulating Expression of Survivin in Nasopharyngeal Carcinoma

EBV-LMP1 targeted DNAzyme enhances radiosensitivity by inhibiting tumor angiogenesis via the JNKs/HIF-1 pathway in nasopharyngeal carcinoma.

Silencing of LMP1 Induces Cell Cycle Arrest and Enhances Chemosensitivity Through Inhibition of AKT Signaling Pathway in EBV-Positive Nasopharyngeal Carcinoma Cells

Bleomycin induced EBV-specific gastric epithelial cell death is enhanced by LMP2A

Study of Apoptosis Regulated by Epstein-Barr Virus Encoded Latent Membrane Protein 1 Using Apoptosis cDNA Expression Array

Synthetic BZLF1-targeted transcriptional activator for efficient lytic induction therapy against EBV-associated epithelial cancers

Zinc Finger E‐box Binding Factor 1 Plays a Central Role in Regulating Epstein‐Barr Virus (EBV) Latent‐lytic Switch and Acts As a Therapeutic Target in EBV‐associated Gastric Cancer

Epstein-Barr Virus Latent Membrane Protein 1 Subverts IMPDH pathways to drive B-cell oncometabolism

Latent Membrane Protein 1 Promotes Tumorigenesis Through Upregulation of PGC1β Signaling Pathway

()-Epigallocatechin-3-gallate Inhibits EBV Lytic Replication Via Targeting LMP1-Mediated MAPK Signal Axes.

[Inhibiting Target Gene Expression and Controlling Growth of Epstein-Barr Virus Transformed Cells by Antisense RNA Transcripts].

EBV LMP1-C terminal binding affibody molecule downregulates MEK/ERK/p90RSK pathway and inhibits the proliferation of nasopharyngeal carcinoma cells in mouse tumor xenograft models